Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
Date:1/29/2009

Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufac
'/>"/>
SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
2. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
3. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
4. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
5. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
6. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
9. Omnitura Therapeutics Announces Private Placement Financing
10. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Nottingham have made a major breakthrough that could help shape ... that 3-D molecular structures can be built on a surface. ... the development of new nano devices such as cutting-edge optical ... paper published in the prestigious journal Nature Chemistry , ...
... -- The review process being used by the Food and ... salmon fails to weigh the full effects of the fish,s ... in this week,s Science . The salmon, whose ... become the first genetically modified animal approved for human consumption ...
... Crescent Healthcare today announced a planned expansion of ... lease to open an infusion pharmacy in Totowa, New ... to current patients in Massachusetts, Maryland, New York, New ... Island. In addition to supporting current ...
Cached Biology Technology:World-first to provide building blocks for new nano devices 2FDA review on transgenic salmon too narrow 2FDA review on transgenic salmon too narrow 3Crescent Healthcare Expands East Coast Presence 2
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
(Date:4/17/2014)... devastate honeybees in Europe, Asia and the United States ... to be impacting native honeybee populations at this time, ... pests include including Nosema microsporidia and ... be resilient to these invasive pests, which suggests to ... Europe, Asia and the United States currently are not ...
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... email messages, from bananas to home-grown tomatoes: everything we buy, produce ... called a "footprint". And if you want to be a good ... can use to understand just how big your footprint is ... But what if you are a government decision maker and ...
... generate a lot of smoke visible on NASA satellite imagery. ... smoke to the north-northeast and into Wyoming and southwestern Nebraska ... located approximately 15 miles west of Fort Collins, Colo., and ... been lost, according to the U.S. Forest Service. More than ...
... an issue faced by teenagers and young women, but a new ... women aged 50 and over, 3.5% report binge eating, nearly 8% ... The study published in the International Journal of Eating Disorders ... shape negatively impacted on their life. The researchers, led by ...
Cached Biology News:A virtual crystal ball 2A virtual crystal ball 3A virtual crystal ball 4Eating disorder behaviors and weight concerns are common in women over 50 2
Request Info...
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
... Cary 50 Microplate Reader accessory ... per analysis by extending the ... award-winning Cary 50 instruments. Use ... 384 samples in microlitre volumes, ...
... use with T4 Polynucleotide Kinase for ... ends) of nucleic acids. In the ... the 5' phosphate group from DNA ... Gamma-phosphate of ATP to the free ...
Biology Products: